Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT5528 in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07450859Phase 2Recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nuzefatide pevedotin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Bicycle Therapeutics. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2026; status: recruiting.
02
Drugs
nuzefatide pevedotin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07450859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450859.